Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OrganonOGN +0.15%71 Earnings Yield (Joel Greenblatt) % is 11.39% as of Mar. 2026, which is 7% above its 10-year median of 10.61. GuruFocus rates OGN with a GF Score™ of 71/100 and a GF Value™ of $14.53 (Fairly Valued). The stock has 10 warning signs investors should review. Among 1,010 Drug Manufacturers companies, Organon ranks better than 79.5% on this metric.
Organon's Enterprise Value for the quarter that ended in Mar. 2026 was $9,026 Mil.
Organon's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $1,028 Mil. Organon's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 11.39%.
The historical rank and industry rank for Organon's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
OGN'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 8.59 Med: 10.61 Max: 26.73
Current: 9.34
During the past 8 years, the highest Earnings Yield (Joel Greenblatt) of Organon was 26.73%. The lowest was 8.59%. And the median was 10.61%.
OGN's Earnings Yield (Joel Greenblatt) % is ranked better than 79.5% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 3.34
vs OGN: 9.34
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Organon's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 40.18%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Organon Earnings Yield (Joel Greenblatt) % Related Terms
Organon Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Organon's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Organon's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organon Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organon's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Organon's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Organons Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Organon's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,028 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 11.39% mean?
Organon (OGN) has a Earnings Yield (Joel Greenblatt) % of 11.39% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Organon and its competitors. This is near median its historical median of 10.61. Over the past decade, Organon's Earnings Yield (Joel Greenblatt) % has ranged from 8.59 to 26.73. According to the industry distribution chart, Organon ranks #207 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 20.5%.
Is Organon's Earnings Yield (Joel Greenblatt) % too high?
Organon's current Earnings Yield (Joel Greenblatt) % of 11.39% is near median its 10-year median of 10.61. Over the past 10 years, this metric has ranged from a low of 8.59 to a high of 26.73. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.34. Organon's value of 11.39% is 241% above this industry median. Based on the distribution chart, Organon ranks #207 out of 1010 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organon has a GF Score™ of 71/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Organon's Earnings Yield (Joel Greenblatt) % compare to AMRN and SCLX?
According to the Drug Manufacturers industry distribution chart, Organon ranks #207 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This places Organon in the top 21% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.34. Organon's value of 11.39% is 241% above this benchmark. Historically, Organon's own Earnings Yield (Joel Greenblatt) % has ranged from 8.59 to 26.73 over the past decade. While the company's 10-year median is 10.61 vs. the industry median of 3.34, Organon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.34, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organon's current Earnings Yield (Joel Greenblatt) % of 11.39% is 241% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Organon and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organon's current Earnings Yield (Joel Greenblatt) % is 11.39%, which is near median its own 10-year median of 10.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organon stock overvalued right now?
Based on GuruFocus' analysis, Organon (OGN) is currently considered Fairly Valued. The stock's GF Value™ is $14.53, compared to a current price of $13.54 — trading 6.8% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 11.39%, which is near median its 10-year median of 10.61 and 241% above the Drug Manufacturers industry median of 3.34. Organon's overall GF Score™ is 71/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Organon (OGN), the current Earnings Yield (Joel Greenblatt) % is 11.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organon (OGN) Overvalued in 2026?
Based on GuruFocus' analysis, Organon stock appears to be undervalued.
The current stock price of $13.54 is trading 6.8% below its estimated GF Value™ of $14.53.
GuruFocus considers Organon to be Fairly Valued.
Key valuation signals for OGN:
Earnings Yield (Joel Greenblatt) %: 11.39% (near median its 10-year median of 10.61)
GF Value™: $14.53 vs. price of $13.54 (6.8% below fair value)
Industry Position: 241% above the Drug Manufacturers median (#207 of 1010)
No single metric tells the full story. See the OGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
71GF Score
Get the complete analysis for OGN
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OGN has been successfully added to your 
